FDA scaling for NTIDs [Design Issues]

posted by krishna – India, 2013-01-18 11:04 (4538 d 19:09 ago) – Posting: # 9889
Views: 7,949

Hi Helmut,

Thanks for your reply.

❝ Hhm, \(\small{\sqrt{0.80\times 0.93}\neq 0.86}\). ;-) If I interpret your example right the study was a full replicate in 32 subjects.


It is 86.25.

❝ The study passes all criteria. What is the problem?


My problem is, here %(T/R): 86.25, it is far way from the 100 and R-R %CV: 26. Due to higher CV it is passing SABE (it would have been failed in SABE if it had low variability). Then how test can be assured with therapeutic equivalence as Reference with out point estimate constraint ?

Thanks,

Krishna.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
24 visitors (0 registered, 24 guests [including 19 identified bots]).
Forum time: 07:13 CEST (Europe/Vienna)

Reach for the stars,
even if you have to stand on a cactus.    Susan Longacre

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5